Clearside Biomedi (CLSD)

$0.32 -0.03 (-8.61%)
Market Cap 26.06M
Revenue (ttm) 1.66M
Net Income (ttm) -34.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,069.28%
Debt to Equity Ratio 0.00
Volume 1,351,424
Avg Vol 5,568,396
Day's Range N/A - N/A
Shares Out 78.51M
Stochastic %K 52%
Beta 2.11
Analysts Sell
Price Target $4.00

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 270 3631
Fax: 678 270 4033
Address:
900 North Point Parkway, Suite 200, Alpharetta, United States
Redposition
Redposition Sep. 16 at 9:13 PM
$CLSD Uncertainty is killing the stock price but I think they will do fine 🙂
0 · Reply
Dasmin
Dasmin Sep. 16 at 8:09 PM
$CLSD I admire the idiot trying to reverse jinx it. There’s nothing stopping the price from going to zero except the company people doing the talking. Nothing YOU say on here will move the needle.
0 · Reply
111ggg
111ggg Sep. 16 at 7:51 PM
$CLSD How is that mountain slope looking now. $1 looking sooner then I thought.
0 · Reply
maphere
maphere Sep. 16 at 4:24 PM
$CLSD This is why we're all still here in hopes to be another VOR...or at least better than where we're at now.
1 · Reply
111ggg
111ggg Sep. 16 at 2:55 PM
$CLSD Price getting closer to $1 day by day. Chapter 7 or 11 should be announced within next 6 months. If folks have not read last 10-Q, do so. Concentrate on commentary toward end of report.
1 · Reply
TwongStocks
TwongStocks Sep. 15 at 8:31 PM
Today's reverse split results. 2 of 3 closed green: $BDSX 1 for 20 Previous close $0.3751, $7.502 split-adjusted Intraday high $7.85 Today's close $7.60 🟢Up 1.31% $CLSD 1 for 15 Previous close $0.3195, $4.7925 split-adjusted Intraday high $4.43 Today's close $3.95 🔴Down 17.58% $SDOT 1 for 10 Previous close $0.7276, $7.276 split-adjusted Intraday high $8.25 Today's close $8.25 🟢Up 13.39%
1 · Reply
N0St0pL0ss
N0St0pL0ss Sep. 15 at 8:30 PM
$CLSD 💰
1 · Reply
JaumeIII
JaumeIII Sep. 15 at 7:32 PM
$CLSD Don’t understand the logic of selling today at .26 pre split when you could have sold last week at .30+
1 · Reply
valueforme
valueforme Sep. 15 at 6:59 PM
$CLSD Still not enough pain. Should reach below $3
1 · Reply
111ggg
111ggg Sep. 15 at 2:49 PM
$CLSD whoops...my bad, only down 13%.
0 · Reply
Latest News on CLSD
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

Aug 26, 2025, 8:05 AM EDT - 21 days ago

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Jul 23, 2025, 7:05 AM EDT - 7 weeks ago

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Jul 17, 2025, 7:05 AM EDT - 2 months ago

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Jun 17, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

May 21, 2025, 7:05 AM EDT - 4 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 4 months ago

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

May 9, 2025, 7:05 AM EDT - 4 months ago

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 8, 2025, 7:05 AM EDT - 4 months ago

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

May 1, 2025, 7:05 AM EDT - 4 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:05 AM EDT - 6 months ago

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Mar 27, 2025, 8:31 PM EDT - 6 months ago

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 24, 2025, 7:05 AM EDT - 6 months ago

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Mar 20, 2025, 7:05 AM EDT - 6 months ago

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Mar 12, 2025, 7:05 AM EDT - 6 months ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Mar 6, 2025, 7:05 AM EST - 6 months ago

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Feb 20, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Feb 10, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Feb 4, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Jan 28, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Jan 22, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Dec 19, 2024, 7:05 AM EST - 9 months ago

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Nov 25, 2024, 7:05 AM EST - 10 months ago

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 8:37 PM EST - 10 months ago

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Nov 7, 2024, 9:05 AM EST - 11 months ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Nov 6, 2024, 7:05 AM EST - 11 months ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Nov 4, 2024, 7:05 AM EST - 11 months ago

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Oct 31, 2024, 7:05 AM EDT - 11 months ago

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Oct 22, 2024, 7:05 AM EDT - 11 months ago

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Oct 9, 2024, 6:30 AM EDT - 1 year ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Aug 1, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Jul 24, 2024, 11:23 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Jul 22, 2024, 12:00 PM EDT - 1 year ago

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Jul 11, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Jun 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Why Is Clearside Biomedical Stock Gaining Today?

Jun 25, 2024, 12:54 PM EDT - 1 year ago

Why Is Clearside Biomedical Stock Gaining Today?

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

Jun 12, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 21, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

May 9, 2024, 9:14 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

May 8, 2024, 4:15 PM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Apr 16, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 18, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 12:47 AM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Feb 29, 2024, 7:05 AM EST - 1 year ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Redposition
Redposition Sep. 16 at 9:13 PM
$CLSD Uncertainty is killing the stock price but I think they will do fine 🙂
0 · Reply
Dasmin
Dasmin Sep. 16 at 8:09 PM
$CLSD I admire the idiot trying to reverse jinx it. There’s nothing stopping the price from going to zero except the company people doing the talking. Nothing YOU say on here will move the needle.
0 · Reply
111ggg
111ggg Sep. 16 at 7:51 PM
$CLSD How is that mountain slope looking now. $1 looking sooner then I thought.
0 · Reply
maphere
maphere Sep. 16 at 4:24 PM
$CLSD This is why we're all still here in hopes to be another VOR...or at least better than where we're at now.
1 · Reply
111ggg
111ggg Sep. 16 at 2:55 PM
$CLSD Price getting closer to $1 day by day. Chapter 7 or 11 should be announced within next 6 months. If folks have not read last 10-Q, do so. Concentrate on commentary toward end of report.
1 · Reply
TwongStocks
TwongStocks Sep. 15 at 8:31 PM
Today's reverse split results. 2 of 3 closed green: $BDSX 1 for 20 Previous close $0.3751, $7.502 split-adjusted Intraday high $7.85 Today's close $7.60 🟢Up 1.31% $CLSD 1 for 15 Previous close $0.3195, $4.7925 split-adjusted Intraday high $4.43 Today's close $3.95 🔴Down 17.58% $SDOT 1 for 10 Previous close $0.7276, $7.276 split-adjusted Intraday high $8.25 Today's close $8.25 🟢Up 13.39%
1 · Reply
N0St0pL0ss
N0St0pL0ss Sep. 15 at 8:30 PM
$CLSD 💰
1 · Reply
JaumeIII
JaumeIII Sep. 15 at 7:32 PM
$CLSD Don’t understand the logic of selling today at .26 pre split when you could have sold last week at .30+
1 · Reply
valueforme
valueforme Sep. 15 at 6:59 PM
$CLSD Still not enough pain. Should reach below $3
1 · Reply
111ggg
111ggg Sep. 15 at 2:49 PM
$CLSD whoops...my bad, only down 13%.
0 · Reply
Del_Gue
Del_Gue Sep. 15 at 2:39 PM
$CLSD What a disaster.
1 · Reply
111ggg
111ggg Sep. 15 at 2:36 PM
$CLSD My mistake...now almost 21% drop Look for 2 area by next week or two.
0 · Reply
111ggg
111ggg Sep. 15 at 2:22 PM
$CLSD Now down 17%. Say goodbye to 4. Anyone who buys this stock is insane as to investing or trading stocks. If you can even short the stock, you are a genius. This from a long term holder of shares. I admit to my past stupidity.
1 · Reply
UnicornPicks
UnicornPicks Sep. 15 at 1:56 PM
$BLNE $RCEL $LVLU $CLSD lets goooo
0 · Reply
111ggg
111ggg Sep. 15 at 1:40 PM
$CLSD As I stated last week, 90% of the time, price goes down after r/s. Now down 15% after 5 minutes.
1 · Reply
rando321456
rando321456 Sep. 15 at 1:32 PM
$CLSD Hmm guess they went into that without a pr on hand, another point towards abject incompetence on leadership's part
1 · Reply
TwongStocks
TwongStocks Sep. 15 at 11:45 AM
$BDSX $CLSD $SDOT All three with reverse splits today. Trading will resume at 9:00am ET with the reverse splits in effect. RS details in the quoted post.
0 · Reply
rando321456
rando321456 Sep. 15 at 4:04 AM
$CLSD Hmmm
1 · Reply
PaulLaurent
PaulLaurent Sep. 14 at 10:10 PM
🚫📉 Zero Borrow Stocks (Excluding Naked Shorts) 💥🚫 $CLSD $ASST $NAT $ADXN $FDWM
1 · Reply
Dasmin
Dasmin Sep. 14 at 3:59 PM
$CLSD What is the most likely price action course after the split tomorrow?
3 · Reply
rando321456
rando321456 Sep. 13 at 10:27 PM
$CLSD @JaumeIII was asking what type of deal around CLS-AX we'd be looking at for HCR to give those concessions. I would say it almost has to be 40-50 million dollars in near term milestones.(Assuming a technical change of control is happening)
2 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Sep. 13 at 11:56 AM
$CLSD ** Clearside Biomedical (CLSD) has a reverse stock split scheduled for Monday, September 15, 2025. ​Here are the key details: ​Split Ratio: 1-for-15 reverse stock split. The new float will be approximately 4.54 million shares.
0 · Reply